National Institutes of Health to Grant Exclusive License for Cancer Treatment Compound

Summary

The National Institutes of Health is considering granting an exclusive license to Emiliem, Inc. to use a novel mTOR kinase inhibitor, LY303511, for the treatment of certain types of cancer and proliferative disorders, excluding stenosis and restenosis.